[en] Rheumatoid arthritis (RA) is one of the most appropriate conditions for the application of personalised medicine as a high degree of heterogeneity has been recognised, which remains to be explained. Such heterogeneity is also reflected in the large number of treatment targets and options. A growing number of biologics as well as small molecules are already in use and there are promising new drugs in development. In order to make the best use of treatment options, both targeted and non-targeted biomarkers have to be identified and validated. To this aim, new rules are needed for the interaction between academia and industry under regulatory control. Setting up multi-centre biosample collections with clear definition of access, organising early, possibly non-committing discussions with regulatory authorities, and defining a clear route for the validation, qualification and registration of the biomarker-drug combination are some of the more critical areas where effective collaboration between the drug industry, academia and regulators is needed.
Ethgen, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects spécifiques
Mitlak, B.
Ormarsdottir, S.
RAO, Rita Flora ; Centre Hospitalier Universitaire de Liège - CHU > Néonatologie non intensive NDB
Tsouderos, Y.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
Smolen J S, Boers M, Abadie EC, e t al. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2011;Jan 17. [Epub ahead of print].
Klareskog L., Stolt P, Lundberg K, e t al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
Klareskog L., Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-672
M aksymowych W P, Fitzgerald O, Wells GA, e t al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009;36:1792-1799
Aletaha D., Neogi T, Silman AJ, e t al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-1588
Rantapää-Dahlqvist S., de Jong BA, Berglin E, e t al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-2749 (Pubitemid 37280601)
Kraft P., Hunter DJ. Genetic risk prediction-are we there yet? N Engl J Med 2009;360:1701-1703
Van de Sande M G, de Hair MJ, van der Leij C, e t al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-777
Van Baarsen L G, Bos WH, Rustenburg F, e t al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010;62:694-704.
Goekoop-Ruiterman Y P, de Vries-Bouwstra JK, Allaart CF, e t al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2008;58 (2 Suppl) : S126-S135
Garnero P., Jouvenne P, Buchs N, e t al. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: Assessment with serum type I collagen breakdown products. Bone 1999;24:381-385 (Pubitemid 29134976)
Del Rincón I., Freeman GL, Haas RW, e t al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-3423 (Pubitemid 41612207)
Kawashima M., Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: Link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 2005;64:415-418 (Pubitemid 40283052)
Verweij C.L. Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res Ther 2009;11:115.
Wijbrandts C A, Dijkgraaf MG, Kraan MC, e t al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008;67:1139-1144
Marotte H., Arnaud B, Diasparra J, e t al. A ssociation between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008;58:1258-1263 (Pubitemid 351705914)
Goldstein D.B. Common genetic variation and human traits. N Engl J Med 2009;360:1696-1698
Daly A K, Donaldson PT, Bhatnagar P, e t al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-819
Keane J., Gershon S, Wise RP, e t al. T uberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104
Carson K R, Evens AM, Richey EA, e t al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840
Bartelds G M, Krieckaert CL, Nurmohamed MT, e t al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-1468
Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med 2009;360:1759-1768
Kallberg H., Padyukov L, Plenge RM, e t al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-875 (Pubitemid 46668455)
Toonen E J, Barrera P, Radstake TR, e t al. Gene expression profiling in rheumatoid arthritis: Current concepts and future directions. Ann Rheum Dis 2008;67:1663-1669
Hirschhorn J.N. Genomewide association studies-illuminating biologic pathways. N Engl J Med 2009;360:1699-1701
Manzo A., Pitzalis C. Lymphoid tissue reactions in rheumatoid arthritis. Autoimmun Rev 2007;7:30-34 (Pubitemid 350011066)
Humby F., Manzo A, Kirkham B, e t al. T he synovial membrane as a prognostic tool in rheumatoid arthritis. Autoimmun Rev 2007;6:248-252 (Pubitemid 46290648)
Wijbrandts C A, Vergunst CE, Haringman JJ, e t al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007;56:3869-3871 (Pubitemid 350100720)
Smith M D, Baeten D, Ulfgren AK, e t al. Standardisation of synovial tissue infiltrate analysis: How far have we come? How much further do we need to go? Ann Rheum Dis 2006;65:93-100. (Pubitemid 41815646)
Hamburg M A, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-304
Piccart-Gebhart M J, Procter M, Leyland-Jones B, e t al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 (Pubitemid 41464705)
Kraus V B, Burnett B, Coindreau J, e t al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil 2011;19:515-542
Goodsaid FM, Mendrick DL. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010;2:47ps44.
Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.